Filing Details

Accession Number:
0001578563-17-000011
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-15 17:12:43
Reporting Period:
2017-11-13
Accepted Time:
2017-11-15 17:12:43
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1560241 G1 Therapeutics Inc. GTHX () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1033409 N Fredric Eshelman C/o G1 Therapeutics, Inc.
79 T.w. Alexander Drive
Research Triangle Park NC 27709
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-13 250,000 $19.73 250,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 3,439,151 Indirect See Footnote
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Option (right to buy) $15.55 2027-07-11 20,000 20,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2027-07-11 20,000 20,000 Direct
Footnotes
  1. Eshelman Ventures, LLC is the record holder of the securities. Dr. Fredric Eshelman is the founder and principal of Eshelman Ventures, LLC and may be deemed to beneficially own the securities held by Eshelman Ventures, LLC. Dr. Eshelman disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
  2. The stock option will vest in thirty-six monthly installments at the end of each successive month following July 11, 2017, subject to the Reporting Person's continued service as a director.